Vise Technologies Inc. Takes Position in CVS Health Corporation $CVS

Vise Technologies Inc. purchased a new position in CVS Health Corporation (NYSE:CVS) during the 2nd quarter, HoldingsChannel.com reports. The fund purchased 29,255 shares of the pharmacy operator’s stock, valued at approximately $2,018,000.

A number of other hedge funds have also recently bought and sold shares of the business. Hazlett Burt & Watson Inc. boosted its stake in shares of CVS Health by 10.9% during the 2nd quarter. Hazlett Burt & Watson Inc. now owns 1,682 shares of the pharmacy operator’s stock valued at $117,000 after buying an additional 165 shares during the last quarter. Williams Financial LLC boosted its stake in CVS Health by 2.5% during the 2nd quarter. Williams Financial LLC now owns 6,923 shares of the pharmacy operator’s stock valued at $478,000 after acquiring an additional 167 shares during the last quarter. Hemington Wealth Management grew its holdings in CVS Health by 33.7% during the 1st quarter. Hemington Wealth Management now owns 682 shares of the pharmacy operator’s stock worth $46,000 after acquiring an additional 172 shares in the last quarter. Sumitomo Life Insurance Co. increased its position in shares of CVS Health by 1.0% in the 1st quarter. Sumitomo Life Insurance Co. now owns 17,114 shares of the pharmacy operator’s stock worth $1,159,000 after purchasing an additional 174 shares during the last quarter. Finally, GW&K Investment Management LLC lifted its position in shares of CVS Health by 39.4% during the first quarter. GW&K Investment Management LLC now owns 637 shares of the pharmacy operator’s stock worth $43,000 after purchasing an additional 180 shares during the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.

Analyst Upgrades and Downgrades

CVS has been the subject of several research analyst reports. Zacks Research lowered CVS Health from a “strong-buy” rating to a “hold” rating in a report on Monday, September 8th. Sanford C. Bernstein boosted their price target on CVS Health from $72.00 to $77.00 and gave the company a “market perform” rating in a report on Friday, September 5th. Bernstein Bank reduced their price objective on CVS Health from $78.00 to $72.00 and set a “market perform” rating on the stock in a research note on Wednesday, July 16th. Barclays lifted their price objective on shares of CVS Health from $80.00 to $87.00 and gave the stock an “overweight” rating in a report on Thursday, September 4th. Finally, Mizuho increased their target price on shares of CVS Health from $76.00 to $88.00 and gave the stock an “outperform” rating in a report on Thursday, October 9th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $89.45.

Insider Buying and Selling

In other CVS Health news, Director Anne A. Finucane sold 7,500 shares of CVS Health stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $71.02, for a total transaction of $532,650.00. Following the sale, the director owned 22,156 shares of the company’s stock, valued at $1,573,519.12. The trade was a 25.29% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.22% of the stock is currently owned by corporate insiders.

CVS Health Stock Performance

CVS stock opened at $79.73 on Wednesday. CVS Health Corporation has a 1 year low of $43.56 and a 1 year high of $85.15. The stock has a market capitalization of $101.22 billion, a price-to-earnings ratio of 209.83, a PEG ratio of 0.87 and a beta of 0.60. The company has a debt-to-equity ratio of 0.83, a quick ratio of 0.62 and a current ratio of 0.83. The stock’s fifty day moving average is $77.36 and its two-hundred day moving average is $69.67.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Wednesday, October 29th. The pharmacy operator reported $1.60 earnings per share for the quarter, topping analysts’ consensus estimates of $1.36 by $0.24. The business had revenue of $102.87 billion for the quarter, compared to analysts’ expectations of $98.85 billion. CVS Health had a net margin of 0.12% and a return on equity of 11.45%. The company’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter last year, the company earned $1.09 EPS. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. On average, research analysts predict that CVS Health Corporation will post 5.89 EPS for the current year.

CVS Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, November 3rd. Investors of record on Thursday, October 23rd were issued a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a yield of 3.3%. The ex-dividend date of this dividend was Thursday, October 23rd. CVS Health’s dividend payout ratio is 700.00%.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.